Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AdAPT-001

Phase 2Biologic

EEpicentRx, Inc.

AdAPT-001 is one of 16 biologic programs targeting Solid Tumor, Adult. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

15

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor, AdultActive, not recruiting

Solid Tumor, AdultPhase 2

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Solid Tumor, Adult

#DrugCompanyPhaseTrials

Keytruda

Avastin

Jakafi

Tagrisso

Rybrevant

Johnson & Johnson

Imjudo

Imfinzi

Alimta

EEagle Pharmaceuticals, Inc.

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Alimta

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Solid Tumor, Adult

NCT04673942

Clinical

Trials by Indication[1]

Solid Tumor, Adult1 trial

An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors

Active, not recruiting·EEpicentRx, Inc.·Phase 2·NCT04673942·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AdAPT-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AdAPT-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AdAPT-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EpicentRx, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: EEpicentRx, Inc.

Related News